Navigation Links
InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
Date:11/5/2013

ospectus supplement and the accompanying prospectus relating to the offering may be obtained from Goldman, Sachs & Co. (Attn: Prospectus Department, 200 West Street, New York, New York 10282, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com or by calling 1-866-471-2526) or J.P. Morgan Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 866-803-9204).  When available, electronic copies of the prospectus supplement may be obtained by visiting EDGAR on the SEC's website at http://www.sec.gov/.

This announcement does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.  Any offer, if at all, will be made only by means of a prospectus supplement and the accompanying prospectus, forming a part of the effective registration statement.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and specialty fibrotic diseases.

Forward-Looking Statements
This news release contains forward-looking statements, including statements relating to InterMune's expectations regarding the completion, timing and size of the proposed public offering and its uses of proceeds from the proposed offering.  These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and InterMune cautions investors no
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
2. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
3. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
4. InterMune To Release First Quarter Financial Results On April 24
5. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune To Release Third Quarter Financial Results On November 7
8. InterMune To Present At JMP Securities Healthcare Conference
9. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
10. InterMune to Present at J. P. Morgan Healthcare Conference
11. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... September 1, 2010, ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Primary Endpoint in Second Phase III Trial in VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... that a new market research report is available ... - Pipeline Assessment and Market Forecasts to 2017 ... Women,s Infertility - Pipeline Assessment and Market ... industry analysis specialist, has released its new report, ...
Cached Biology Technology:EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 2EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 3EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 4EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 5EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 6EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6
(Date:7/9/2014)... ranges in which animals can be found, concern mounts ... an increased range for a host mean new territory ... a team of UC Santa Barbara scientists, including parasitologists ... in the Journal of Biogeography , Hechinger, Kuris ... may happen: Hosts may actually lose their parasites when ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
(Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... Global Information Inc is pleased to offer attendees their ... the world. Early Bird registration prices end as early ... to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ) ... | San Francisco, California CHI,s High-Content Analysis ...
... ARLINGTON, Va.Dr. John P. Holdren, White House Office of ... powerful roster of military and government leaders at the ... Conference and ASNE Expo, officials announced Sept. 18. ... S&T and co-chair of the President,s Council of Advisors ...
... is one of the most serious complications related to ... grown in Peru and Chile is a relative of ... The maize is rich in anthocyanins (also known as ... from the Department of Food and Nutrition and Department ...
Cached Biology News:International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4ONR lines up speakers and technologies for 2012 Naval Conference 2Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease 2
... cell with multi-casting chamber is used for handcasting ... format handcast (8.3 x 7.3 cm) or precast ... 3.4-4.4 L of buffer and includes an electrophoresis ... an external refrigerated circulator (not included), lid with ...
...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
...
Biology Products: